Found Safety, Regulation & Compliance Posture: An Independent Review

How Found Operates as a Telehealth Weight-Loss Platform

Found connects patients with licensed prescribers who evaluate candidacy for FDA-approved weight-loss medications through asynchronous and synchronous video consultations. The platform pairs pharmacotherapy with behavioral coaching delivered via its mobile app.

Unlike compounding-only telehealth startups that emerged during the 2022-2024 semaglutide shortage, Found built its model around branded, FDA-approved GLP-1 receptor agonists and non-GLP-1 adjuncts. That distinction matters. The FDA's October 2023 warning about compounded semaglutide products flagged dosing inconsistencies, sterility concerns, and adverse-event reports tied to compounding pharmacies operating outside cGMP standards. Found's reliance on branded products from Novo Nordisk (Wegovy, Saxenda) and other established manufacturers sidesteps this specific regulatory risk.

The platform requires patients to complete a medical intake that includes weight history, comorbidities, current medications, and contraindications. Prescribers then select from a formulary that spans GLP-1s, bupropion-naltrexone (Contrave), metformin (off-label for weight), and topiramate (off-label). This multi-drug formulary is consistent with the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity, which recommends individualized medication selection based on patient phenotype and comorbidity profile [1].

Regulatory Compliance and State Licensing

Found's prescribers must hold active, unrestricted medical licenses in the states where they treat patients. This is a baseline legal requirement under the Ryan Haight Act and state medical board regulations, not a differentiator.

What does differentiate Found from some competitors is its BCBS partnership structure. Blue Cross Blue Shield plans that include Found as an in-network benefit have conducted their own credentialing and network-adequacy reviews. BCBS credentialing requires verification of board certification, malpractice history, DEA registration, and clinical competency [2]. A plan would not contract with a telehealth vendor whose prescribing practices created outsized liability exposure. This external validation does not guarantee perfect care, but it adds a compliance checkpoint that cash-pay-only platforms lack entirely.

Found's pharmacy fulfillment routes prescriptions through licensed retail and mail-order pharmacies regulated by state boards of pharmacy and the FDA. Prescriptions for branded GLP-1s (Wegovy, Saxenda) go through standard pharmacy benefit channels with REMS-equivalent monitoring where applicable. The FDA's REMS program for Saxenda requires a medication guide to be dispensed with each fill, and Found's pharmacy partners are subject to the same dispensing requirements as any brick-and-mortar pharmacy [3].

Clinical Safety of the Medications Found Prescribes

The safety profile of Found's formulary drugs is well-characterized in large randomized controlled trials. The platform itself does not manufacture or compound medications; it prescribes FDA-approved products whose risk-benefit profiles are already established.

Semaglutide 2.4 mg (Wegovy). The STEP program evaluated semaglutide across multiple populations. In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg weekly achieved 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo. Gastrointestinal adverse events (nausea, diarrhea, vomiting) occurred in 74.2% of the semaglutide group versus 47.9% with placebo, though most were mild to moderate and peaked during dose escalation [4]. The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) among adults with overweight or obesity and established cardiovascular disease, earning Wegovy a cardiovascular risk-reduction indication from the FDA in March 2024 [5].

Liraglutide 3.0 mg (Saxenda). The SCALE Obesity and Prediabetes trial (N=3,731) showed 8.0% mean weight loss with liraglutide versus 2.6% with placebo at 56 weeks. The safety profile mirrored semaglutide's GI-dominant pattern, with nausea affecting 40.2% of treated patients [6].

Bupropion-naltrexone (Contrave). The COR-I trial (N=1,742) demonstrated 6.1% mean weight loss at 56 weeks. The black-box warning for suicidality risk (inherited from bupropion's antidepressant class labeling) requires Found prescribers to screen for psychiatric history before initiation [7].

A responsible telehealth platform must monitor patients for these known adverse effects. Found's model includes follow-up check-ins and dose-titration protocols, though the frequency and depth of monitoring depend on the individual prescriber's clinical judgment rather than a standardized protocol published by the company.

Is Found Legit? Evaluating Trustworthiness Signals

Several objective markers help distinguish legitimate telehealth weight-loss services from those operating in regulatory gray zones.

Found holds an A+ rating with the Better Business Bureau and maintains accreditation, indicating it responds to consumer complaints and meets BBB standards for advertising transparency. Its prescribers appear in state medical board databases with active licenses. The BCBS insurance partnerships, discussed above, add a layer of third-party credentialing that purely cash-pay competitors do not face.

Red flags common among less reputable telehealth weight-loss platforms include: prescribing without a synchronous provider interaction (Found offers both async and video visits), dispensing compounded peptides from unregistered 503B outsourcing facilities, and guaranteeing specific weight-loss outcomes. Found's marketing has generally avoided outcome guarantees, instead referencing the clinical trial data for the medications it prescribes. This aligns with FTC guidance on health-product advertising, which prohibits unsubstantiated efficacy claims [8].

One area that warrants scrutiny: Found's behavioral coaching component. The platform markets "personalized" coaching as part of its subscription. The USPSTF recommends intensive behavioral interventions (defined as 12 or more sessions in the first year) for adults with a BMI of 30 or greater [9]. Whether Found's coaching meets the "intensive" threshold varies by plan tier and patient engagement. Patients should verify the coaching frequency included in their specific subscription before assuming it satisfies clinical guidelines.

Found vs. Alternatives: How It Compares on Safety and Compliance

Comparing Found to other telehealth weight-loss platforms requires evaluating three axes: prescribing legitimacy, medication sourcing, and monitoring infrastructure.

Versus Calibrate. Calibrate also prescribes FDA-approved GLP-1s and pairs them with metabolic coaching. Both platforms use licensed prescribers and branded medications. Calibrate's one-year commitment model may incentivize longer patient-provider relationships, while Found's month-to-month flexibility could lead to shorter treatment durations. Neither model is inherently safer; the American Association of Clinical Endocrinology (AACE) 2023 consensus statement recommends long-term pharmacotherapy for obesity, suggesting that platforms encouraging sustained engagement may produce better outcomes [10].

Versus Ro Body. Ro has prescribed both branded and, during the shortage period, compounded semaglutide. Found's avoidance of compounded products during the 2023-2024 shortage window represents a more conservative compliance posture. The FDA's position has consistently been that compounded versions of drugs with available branded supply are not approved and may pose additional safety risks [11].

Versus Sequence (now Nourish/WeightWatchers Clinic). Sequence's acquisition by WeightWatchers brought it under a larger corporate compliance umbrella. Found remains an independent company, which means its compliance infrastructure is self-governed rather than inherited from a parent organization with existing healthcare regulatory experience.

The table below summarizes key compliance indicators:

| Feature | Found | Calibrate | Ro Body | |---|---|---|---| | FDA-approved drugs only | Yes | Yes | Mixed | | Insurance accepted | Select BCBS | Select plans | Limited | | Licensed prescribers | Yes | Yes | Yes | | Compounded GLP-1s offered | No | No | Yes (historically) | | BBB accredited | Yes | Yes | Yes |

Monitoring, Follow-Up, and Adverse-Event Reporting

The FDA's MedWatch program allows patients and providers to report adverse events for any FDA-approved drug, regardless of prescribing channel [12]. Found's prescribers are subject to the same mandatory adverse-event reporting requirements as any licensed clinician. If a patient experiences a serious adverse event while on a Found-prescribed medication, the prescriber must report it through MedWatch.

Found's follow-up cadence has not been publicly audited by an independent body. The platform states that providers monitor patients during dose titration and through ongoing check-ins, but the specific intervals are not standardized in public-facing documentation. By comparison, the Wegovy prescribing information recommends assessing response at 12 weeks on the maintenance dose and discontinuing if a patient has not achieved at least 5% weight loss [13].

Patients using Found should ask their prescriber three questions to verify adequate monitoring: (1) How often will we have follow-up visits during dose escalation? (2) What is the protocol if I experience persistent GI side effects? (3) At what point will you reassess whether the current medication is working? These questions are consistent with the monitoring framework outlined in the Endocrine Society's 2024 guideline [1].

Cost, Insurance, and Value Considerations

Found's subscription pricing has fluctuated, but as of early 2026, the platform charges approximately $99-$149 per month for its membership, which covers prescriber consultations and coaching. Medication costs are separate and depend on insurance coverage, manufacturer coupons, and pharmacy selection.

For patients with qualifying BCBS plans, Found's membership and medication costs may be partially or fully covered. The Kaiser Family Foundation's 2024 employer health benefits survey found that 44% of large employers now cover at least one anti-obesity medication, up from 26% in 2022 [14]. This trend favors platforms like Found that have established insurance relationships.

Without insurance, branded Wegovy carries a list price of approximately $1,349 per month, though Novo Nordisk's savings program can reduce out-of-pocket costs to as low as $0 for commercially insured patients. Saxenda's list price is approximately $1,400 per month. Found cannot control these manufacturer prices, but its insurance partnerships give enrolled patients a potential cost advantage over cash-pay platforms.

The cost-effectiveness of GLP-1 therapy depends on sustained use. A 2024 analysis published in the Annals of Internal Medicine estimated that semaglutide 2.4 mg is cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) only when cardiovascular risk reduction is included in the model [15]. Patients should weigh this evidence when evaluating whether Found's subscription plus medication costs represent a reasonable investment.

What Found Prescribes and How Prescribing Decisions Are Made

Found's formulary spans five primary medication categories for weight management. Each drug addresses a different mechanism, and prescriber selection depends on patient BMI, comorbidities, prior medication trials, and contraindications.

GLP-1 receptor agonists (semaglutide, liraglutide) are the first-line options for patients with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. This threshold matches the FDA-approved indications for both Wegovy and Saxenda [13]. For patients who cannot access or tolerate GLP-1s, Found prescribers may turn to bupropion-naltrexone, metformin, or topiramate. Metformin and topiramate are used off-label for weight management, a practice supported by evidence but not by a specific FDA weight-loss indication. The American Gastroenterological Association's 2022 clinical practice guideline lists metformin as a conditional recommendation for patients who do not meet GLP-1 criteria or who have concurrent insulin resistance [16].

Found does not prescribe phentermine or other Schedule IV stimulants through its telehealth platform, likely due to the Ryan Haight Act's restrictions on prescribing controlled substances via telemedicine without an in-person evaluation (though temporary COVID-era flexibilities existed, the DEA's final telemedicine rule has tightened requirements) [17]. This limitation actually serves as a compliance signal: platforms willing to prescribe stimulants via telehealth without in-person visits may be operating in a regulatory gray area.

Patients considering Found should receive a 5% body-weight-loss assessment at 12 weeks on maintenance dosing and switch medications if that threshold is not met.